Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136


Proteomic profiling of tumor-initiating cells in HT-29 human colorectal cancer cells.

Lee HN, Park SH, Lee EK, Bernardo R, Kim CW.

Biochem Biophys Res Commun. 2012 Oct 12;427(1):171-7. doi: 10.1016/j.bbrc.2012.09.036. Epub 2012 Sep 17.


Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.

Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N.

Oncol Rep. 2012 Oct;28(4):1301-8. doi: 10.3892/or.2012.1951. Epub 2012 Aug 6.


The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.

Elsaba TM, Martinez-Pomares L, Robins AR, Crook S, Seth R, Jackson D, McCart A, Silver AR, Tomlinson IP, Ilyas M.

PLoS One. 2010 May 19;5(5):e10714. doi: 10.1371/journal.pone.0010714.


CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.


Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.

Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS.

World J Gastroenterol. 2009 May 14;15(18):2258-64.


CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.

Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF.

PLoS One. 2011;6(11):e28053. doi: 10.1371/journal.pone.0028053. Epub 2011 Nov 28.


CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.


CD49f-positive cell population efficiently enriches colon cancer-initiating cells.

Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M.

Int J Oncol. 2013 Aug;43(2):425-30. doi: 10.3892/ijo.2013.1955. Epub 2013 May 24.


Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.

Pitule P, Cedikova M, Daum O, Vojtisek J, Vycital O, Hosek P, Treska V, Hes O, Kralickova M, Liska V.

Biomed Res Int. 2014;2014:432139. doi: 10.1155/2014/432139. Epub 2014 Apr 22.


Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.

Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH, Kim HR.

Int J Oncol. 2015 Apr;46(4):1582-8. doi: 10.3892/ijo.2015.2844. Epub 2015 Jan 23.


CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.

Choy W, Nagasawa DT, Trang A, Thill K, Spasic M, Yang I.

Neurosurg Clin N Am. 2012 Jul;23(3):391-405. doi: 10.1016/ Epub 2012 Jun 5. Review.


Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.


The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.

Koyama-Nasu R, Takahashi R, Yanagida S, Nasu-Nishimura Y, Oyama M, Kozuka-Hata H, Haruta R, Manabe E, Hoshino-Okubo A, Omi H, Yanaihara N, Okamoto A, Tanaka T, Akiyama T.

PLoS One. 2013;8(1):e53710. doi: 10.1371/journal.pone.0053710. Epub 2013 Jan 10.


The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.

Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A.

J Pathol. 2009 Dec;219(4):427-34. doi: 10.1002/path.2597.


Prognostic role of CD133 expression in colorectal cancer: a meta-analysis.

Wang K, Xu J, Zhang J, Huang J.

BMC Cancer. 2012 Dec 5;12:573. doi: 10.1186/1471-2407-12-573.


Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells.

Yusra, Semba S, Yokozaki H.

Int J Oncol. 2012 Jul;41(1):201-10. doi: 10.3892/ijo.2012.1459. Epub 2012 May 2.


Cytometric profiling of CD133+ cells in human colon 
carcinoma cell lines identifies a common core phenotype 
and cell type-specific mosaics.

Gemei M, Di Noto R, Mirabelli P, Del Vecchio L.

Int J Biol Markers. 2013 Sep 27;28(3):267-73. doi: 10.5301/JBM.5000020.


Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.

Kim ST, Sohn I, DO IG, Jang J, Kim SH, Jung IH, Park JO, Park YS, Talasaz A, Lee J, Kim HC.

Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66.


CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.

Cui F, Wang J, Chen D, Chen YJ.

Oncol Rep. 2011 Mar;25(3):701-8. doi: 10.3892/or.2010.1115. Epub 2010 Dec 20.


Cancer stem cells hypothesis and stem cells in head and neck cancers.

Mannelli G, Gallo O.

Cancer Treat Rev. 2012 Aug;38(5):515-39. doi: 10.1016/j.ctrv.2011.11.007. Epub 2011 Dec 23. Review.


Supplemental Content

Support Center